Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2020 / N 4

Возможность применения препарата Костарокс (эторикоксиб) у пациентов с поясничной болью
П.Р. Камчатнов, С.Б. Ханмурзаева, А.В. Чугунов

References

1. GBD 2019 Diseases and Injuries Collaborators 2019. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study. The Lancet 2020 Oct;396(10258):1204-22.
2. Manfrè L, Van Goethem J. Low back pain. In: Diseases of the brain, head and neck, spine 2020–2023. Diagnostic imaging. Hodler J, Kubik-Huch R, von Schulthess G, editors. Cham, Switzerland: Springer; 2020: 225-30.
3. Canizares M, Rampersaud YR, Badley EM. Course of back pain in the Canadian population: trajectories, predictors, and outcomes. Arthritis Care & Research (Hoboken) 2019 Dec;71(12):1660-70.
4. Ita ME, Zhang S, Holsgrove TP, Kartha S, Winkelstein BA. The physiological basis of cervical facet-mediated persistent pain: basic science and clinical challenges. The Journal of Orthopaedic & Sports Physical Therapy 2017 Jul;47(7):450-61.
5. Goode AP, Nelson AE, Kraus VB, Renner JB, Jordan JM. Biomarkers reflect differences in osteoarthritis phenotypes of the lumbar spine: the Johnston County Osteoarthritis Project. Osteoarthritis and Cartilage 2017 Oct;25(10):1672-9.
6. Ruediger T, Horbert V, Reuther A, Kalla PK, Burgkart RH, Walther M, Kinne RW, Mika J. Thickness of the stifle joint articular cartilage in different large animal models of cartilage repair and regeneration. Cartilage 2020 Dec 3. Article first published online. doi.org/10.1177/1947603520976763.
7. Rampersaud YR, Nakamura A, Stephen J. Lumbar spine osteoarthritis. In: Osteoarthritis: pathogenesis, diagnosis, available treatments, drug safety, regenerative and precision medicine. Kapoor LM, Mahomed NN, editors. Cham, Switzerland: Springer; 2015: 61-88.
8. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. The Lancet 2017 Feb;389(10070):736-47.
9. Wong JJ, Côté P, Sutton DA, Randhawa K, Yu H, Varatharajan S, Goldgrub R, Nordin M, Gross DP, Shearer HM, Carroll LJ, Stern PJ, Ameis A, Southerst D, Mior S, Stupar M, Varatharajan T, Taylor-Vaisey A. Clinical practice guidelines for the noninvasive management of low back pain: a systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. European Journal of Pain (London, England) 2017 Feb;21(2):201-16.
10. Cutforth G, Peter A, Taenzer P. The Alberta Health Technology Assessment (HTA) ambassador program: the development of a contextually relevant, multidisciplinary clinical practice guideline for non-specific low back pain: a review. Physiotherapy Canada 2011 Summer;63(3):278-86.
11. Øverås CK, Villumsen M, Axén I, Cabrita M, Leboeuf-Yde C, Hartvigsen J, Mork PJ. Association between objectively measured physical behaviour and neck- and/or low back pain: a systematic review. European Journal of Pain (London, England) 2020 Jul;24(6):1007-22.
12. Oliveira CB, Pinheiro MB, Teixeira RJ, Franco MR, Silva FG, Hisamatsu TM, Ferreira PH, Pinto RZ. Physical activity as a prognostic factor of pain intensity and disability in patients with low back pain: a systematic review. European Journal of Pain (London, England) 2019 Aug;23(7):1251-63.
13. Cherkin DC, Anderson ML, Sherman KJ, Balderson BH, Cook AJ, Hansen KE, Turner JA. Two-year follow-up of a randomized clinical trial of mindfulness-based stress reduction vs cognitive behavioral therapy or usual care for chronic low back pain. JAMA 2017 Feb;317(6):642-4.
14. Wood L, Hendrick PA. A systematic review and meta-analysis of pain neuroscience education for chronic low back pain: short- and long-term outcomes of pain and disability. European Journal of Pain (London, England) 2019 Feb;23(2):234-49.
15. Davin S, Lapin B, Mijatovic D, Fox R, Benzel E, Stilphen M, Machado A, Katzan IL. Comparative effectiveness of an interdisciplinary pain program for chronic low back pain, compared to physical therapy alone. Spine 2019;44(24):1715-22.
16. Roelofs PDDM, Deyo RA, Koes BW, Scholten RJPM, van Tulder MW. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine 2008;33(16):1766-74.
17. Parfenov VA, Yakhno NN, Kukushkin ML, Churyukanov MV, Davydov OS, Golovacheva VA, Isaykin AI, Achkasov EE, Yevzikov GYu, Karateyev AE, Khabirov FA, Shirokov VA. Acute non-specific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Neurology, Neuropsychiatry, Psychosomatics 2018;10(2):4-11 (In Russian).
18. Kamchatnov PR. Improving efficacy and safety of treatment in patients with low back pain. SS Korsakov Journal of Neurology and Psychiatry 2016;116(10):28-33 (In Russian).
19. Warner T, Mitchell J. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB Journal 2004 May;18(7):790-804.
20. Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the USA 2002 Oct;99(21):13926-31.
21. Bapna M, Chauhan LS. The ambidextrous cyclooxygenase: an enduring target. Inflammation and Allergy. Drug Targets 2015;13(6):387-92.
22. Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. The Annals of Pharmacotherapy 2005 May;39(5):854-62.
23. Birbara CA, Puopolo AD, Munoz DR, Sheldon, Mangione A, Bohidar NR, Geba GP; Etoricoxib Protocol 042 Study Group. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. The Journal of Pain 2003 Aug;4(6):307-15.
24. Pallay PM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R, O’Brien K, Mucciola L, Skalky CS, Petruschke RA, Bohidar NR, Geba GP. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scandinavian Journal of Rheumatology 2004;33(4):257-66.
25. Zerbini C, Ozturk ZE, Grifka J, Maini M, Nilganuwong S, Morales R, Hupli M, Shivaprakash M, Giezek H; Etoricoxib CLBP Study Group. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Current Medical Research and Opinion 2005 Dec;21(12):2037-49.
26. Jagannathan H, Thota A, Kumarappa AKB, Kishore G. A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital. Journal of Drug Assessment 2020 Mar;9(1):60-5.
27. Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Current Medical Research and Opinion 2006 Dec;22(12):2365-74.
28. Moore RA, Derry S, McQuay HJ. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthritis Research & Therapy 2008;10(3):R53.
29. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger M, Bao W, Lincoff AM; PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. The New England Journal of Medicine 2016 Dec;375(26):2519-29.
30. Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Current Medical Research and Opinion 2004 Dec;20(12):1899-908.
31. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: a meta-analysis. PLoS One 2018 Jan;13(1):e0190798.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]